{
    "clinical_study": {
        "@rank": "46986", 
        "acronym": "GX-G3", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "GX-G3 12.5 \u03bcg/kg or Placebo"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "GX-G3 25 \u03bcg/kg or Placebo"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "GX-G3 50 \u03bcg/kg or Placebo"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "GX-G3 100 \u03bcg/kg or Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "pharmacokinetics/pharmacodynamics of GX-G3 after single subcutaneous administration in\n      healthy male subjects."
        }, 
        "brief_title": "Phase I Study GX-G3 in Healthy Subjects", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "MTD will be determined by DLT occurrence and frequency, and severity and charactoristic of\n      adverse event, vital sign, physical examination, ECG, Laboratory test, chest-X-ray will be\n      examined for safety evaluation.\n\n      The second purpose is to evaluate pharmacokinetics and pharmacodynamics, and immunogenecity\n      will be evaluated to investigate antibody production."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects may be entered in the study only if they meet all of the following criteria:\n\n          1. Are capable of understanding and complying with the requirements of the study and\n             have voluntarily signed the informed consent form (ICF);\n\n          2. Healthy male volunteers aged 20-45 years;\n\n          3. Have a body weight of 60-90 kg (inclusive), have a body mass index (BMI) equal to or\n             greater than 19 and less than 27 kg/m2;\n\n          4. Are eligible for the study based on screening data (Subjects may participate if\n             Investigator considered eligible after looking at other screening data);\n\n        Exclusion Criteria:\n\n        Subjects presenting with any of the following will not be entered in to the study:\n\n          1. Have a history of or current evidence of disease;\n\n          2. Have percent of white blood cell (WBC) or neutrophil > UNL;\n\n          3. Have count of platelet < 100,000/mm3;\n\n          4. Have the longest length of spleen > 16 cm measured by abdomen ultrasonography ;\n\n          5. Have MSSBP \u2265 140 mmHg or \u2264 90 mmHg and/or MSDBP \u2265 95 mmHg or \u2264 50 mmHg; (BP must be\n             measured after resting for at least 3 minutes)\n\n          6. Have clinically significant arrhythmia by EKG/ECG;\n\n          7. Are positive for HBV, HCV, HIV;\n\n          8. Have a history of allergy/hypersensitivity or ongoing allergy/hypersensitivity to any\n             drug, as judged by the investigator;\n\n          9. Have had any blood donation/ blood loss greater than 400 ml within 8 weeks prior to\n             dosing;\n\n         10. Have participated in another clinical trial with investigational drugs within 8 weeks\n             of screening period;\n\n         11. Any other conditions that are considered inappropriate or unsafe for subjects by the\n             Investigator;\n\n         12. Are considered ineligible by the investigator due to physical findings or laboratory\n             values at the screening assessments;\n\n         13. Have a history of G-CSF treatment;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951027", 
            "org_study_id": "GX-G3_HV_1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Single SC injection", 
                "intervention_name": "GX-G3 12.5 \u03bcg/kg or Placebo", 
                "intervention_type": "Drug", 
                "other_name": "GX-G3(G-CSF-hyFc)"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single SC injection", 
                "intervention_name": "GX-G3 25 \u03bcg/kg or Placebo", 
                "intervention_type": "Drug", 
                "other_name": "GX-G3(G-CSF-hyFc)"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Single SC injection", 
                "intervention_name": "GX-G3 50 \u03bcg/kg or Placebo", 
                "intervention_type": "Drug", 
                "other_name": "GX-G3(G-CSF-hyFc)"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Single SC injection", 
                "intervention_name": "GX-G3 100 \u03bcg/kg or Placebo", 
                "intervention_type": "Drug", 
                "other_name": "GX-G3(G-CSF-hyFc)"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "DLT", 
            "Immunogenecity"
        ], 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "contact": {
                "email": "zeusy@cnuh.co.kr", 
                "last_name": "JeaWoo Kim, M.D.", 
                "phone": "82-42-280-8618"
            }, 
            "facility": {
                "address": {
                    "city": "Jung-gu", 
                    "country": "Korea, Republic of", 
                    "state": "Daejeon", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam National University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "JeaWoo Kim, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jang Hee Hong, M.D., Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects", 
        "overall_official": [
            {
                "affiliation": "Genexine, Inc, Clinical development Department", 
                "last_name": "Sang-In Yang, Ph.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "CHUNGNAM NATIONAL UNIVERSITY HOSPITAL Clinical Research Center", 
                "last_name": "Jae Woo Kim, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "[DLT criteria: CTCAE V4.03]\nHematologic type: grade 3 Hematologic N.O.S, grade 3 or 4 Leukocytosis\nNon-Hematologic: grade 3 N.O.S\nN.O.S: not otherwise specified\nLeukocytosis: continued more than 5 days, grade 3(>100,000 cells/mm3), or grade 4(clinical manifestations of leucostasis; urgent intervention indicated)", 
            "measure": "DLT incidence and frequency after GX-G3 single S.C. injection", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events incidence and frequency at each dose group after GX-G3 single injection", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "AUC/D, Cmax/D, AUC, AUClast, Cmax, tmax, half-life", 
                "measure": "Pharmacokinetics parameters after GX-G3 single injection", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "Emax, Emax, Tmax and AUEClast of absolute neutrophil count(ANC), WBC count and CD34+ cell count", 
                "measure": "Pharmacodynamics parameters after GX-G3 single injection", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }
        ], 
        "source": "Genexine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genexine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}